dasotraline 4mg + dasotraline 6mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Binge Eating Disorder
Conditions
Binge Eating Disorder
Trial Timeline
Mar 31, 2017 → May 16, 2018
NCT ID
NCT03107026About dasotraline 4mg + dasotraline 6mg + Placebo
dasotraline 4mg + dasotraline 6mg + Placebo is a phase 3 stage product being developed by Sumitomo Pharma for Binge Eating Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03107026. Target conditions include Binge Eating Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03107026 | Phase 3 | Completed |
Competing Products
11 competing products in Binge Eating Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Zonegran + sugar pill | Eisai | Phase 3 | 77 |
| Dasotraline + Placebo | Sumitomo Pharma | Phase 2/3 | 65 |
| Dasotraline | Sumitomo Pharma | Phase 3 | 77 |
| Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml + Placebo | Novo Nordisk | Phase 3 | 76 |
| Solriamfetol + Placebo | Jazz Pharmaceuticals | Approved | 82 |
| Sodium Oxybate | Jazz Pharmaceuticals | Phase 2/3 | 62 |
| Solriamfetol 75mg, 150 mg, or 300 mg | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg + Solriamfetol 300 mg + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| RDC-0313 (ALKS 33) + Placebo | Alkermes | Phase 2 | 49 |
| ACT-539313 + Placebo | Idorsia | Phase 2 | 47 |